fbpx

Thyroid Eye Disease

The clinical trial we are recruiting for is a Phase 1/2, Adaptive, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of Lonigutamab in Subjects With Thyroid Eye Disease (TED).

Click for details.

Register your interest